Finance

Lists
BDTX:NASDAQ
Black Diamond Therapeutics Inc
1,92 US$
+1,59%
(+0,030) 1D
5 ოქტ, 12:02:14 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BDTX...
Open
1,90 US$
High
1,92 US$
Low
1,88 US$
Mkt. cap
110,31 მლნ.
Avg. vol.
554,24 ათ.
Volume
217,10 ათ.
52-wk high
4,94 US$
52-wk low
1,60 US$
EPS
-0,74 US$
Beta
3,32
Shares outstanding
57,45 მლნ.
No. of employees
21
Open
1,90 US$
High
1,92 US$
Low
1,88 US$
Mkt. cap
110,31 მლნ.
Avg. vol.
554,24 ათ.
Volume
217,10 ათ.
52-wk high
4,94 US$
52-wk low
1,60 US$
EPS
-0,74 US$
Beta
3,32
Shares outstanding
57,45 მლნ.
No. of employees
21
News stories
From web sources and news partners
About Black Diamond Therapeutics Inc
CEO-
Employees21
Founded2014
Headquarters-
Sector-
Websiteblackdiamondtherapeutics.com
Analyst ratings
Based on 7 analysts giving stock ratings to BDTX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for BDTX in the last 3 months.
Highest
Current 1,92 US$
14,00 US$ (+629,17%)
Average
10,33 US$ (+438,02%)
Lowest
8,00 US$ (+316,67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean McCutcheon
Raymond James
Buy
Maintained
11,00 US$
+472,9%
08/06/2026
Maury Raycroft
Jefferies
Buy
Maintained
10,00 US$
+420,8%
08/06/2026
Robert Driscoll
Wedbush
Buy
Reiterated
14,00 US$
+629,2%
08/06/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
8,00 US$
+316,7%
08/06/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
8,00 US$
+316,7%
08/06/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
11,00 US$
+472,9%
08/06/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/05/2026
Last report
5 აგვ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,17 US$ / -0,20 US$
+15,00%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7,44 მლნ.
6,30 მლნ.
7,00 მლნ.
7,39 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,54 მლნ.
3,97 მლნ.
4,26 მლნ.
4,66 მლნ.
Operating expense
10,98 მლნ.
10,26 მლნ.
11,26 მლნ.
12,06 მლნ.
Total operating expenses
10,98 მლნ.
10,26 მლნ.
11,26 მლნ.
12,06 მლნ.
Operating income
-10,98 მლნ.
-10,26 მლნ.
-11,26 მლნ.
-12,06 მლნ.
Other non operating income
1,32 მლნ.
1,16 მლნ.
1,20 მლნ.
1,23 მლნ.
EBT including unusual items
-8,50 მლნ.
-15,12 მლნ.
-9,04 მლნ.
-9,90 მლნ.
EBT excluding unusual items
-8,50 მლნ.
-7,92 მლნ.
-9,04 მლნ.
-9,90 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8,50 მლნ.
-15,12 მლნ.
-9,04 მლნ.
-9,90 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-0,15
-0,14
-0,16
-0,17
Interest and investment income
1,16 მლნ.
1,18 მლნ.
1,02 მლნ.
922,00 ათ.
Interest expense
-
-
-
-
Net interest expenses
1,16 მლნ.
1,18 მლნ.
1,02 მლნ.
922,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,89 მლნ.
-10,20 მლნ.
-11,23 მლნ.
-12,03 მლნ.
Gain or loss from assets sale
-1,00 ათ.
-3,00 ათ.
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები